Greg Dearborn News Today

Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points ...

Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash...

CAMBRIDGE, Mass., May 20, 2024 -- Foghorn Therapeutics Inc. today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share,...

Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation...

First-in class BRM selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024 ...

First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024

Company presentation and fireside chat on April 11th at 11:45 a.m. ETCAMBRIDGE, Mass., April 05, 2024 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class...

Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader...

28.02.2024 - CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) - Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today ...

CAMBRIDGE, Mass., Jan. 03, 2024 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene...